Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017


News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer buys BlueRock in $600 million bet on stem cell therapies

share with twitter share with LinkedIn share with facebook
share via e-mail
08/08/2019 | 07:18am EDT
FILE PHOTO: Headquarters and main plant of German pharmaceutical and chemical maker Bayer AG in Leverkusen

FRANKFURT (Reuters) - German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics, stepping up investment in a promising new medical area to revive its drug development pipeline.

Having established BlueRock as part of a 2016 joint venture with Versant Ventures, Bayer will acquire the remaining 59.2% stake for about $240 million upfront and an additional $360 million depending on certain development achievements, it said on Thursday.

BlueRock, valued at about $1 billion by the deal, is working on induced pluripotent stem cells (iPSC), made by reprogramming mature body cells to behave like embryonic stem cells that are injected to restore diseased tissue in patients.

While the biotech firm is looking to treat neurology, cardiology and immunology conditions, its most advanced program will begin testing on Parkinson's disease patients by the end of this year in a U.S. regulated trial.

"We get access and full ownership in one of the most exciting areas of biology that exist currently," Bayer's head of pharmaceuticals, Stefan Oelrich, said in an interview.

Parkinson's, a debilitating neurological disease that cannot be reversed, affects more than 7 million people globally.

Bayer has already tested the waters in iPSC research. In April it struck a deal with unlisted Khloris Biosciences to jointly develop anti-cancer vaccines based on iPSCs.

In July, it followed up with a $215 million investment in a minority stake in Century Therapeutics, another U.S. biotech group with a focus on iPSCs.

But Oelrich said the outright takeover of BlueRock marks Bayer's "foundational piece" because previous iPSC engagement had been via minority stakes and in much earlier phases of drug development.

Scientists at Kyoto University in Japan have been pioneering the technology, saying in July they would be the first to run a trial with iPSC in Parkinson's patients, having previously run tests on monkeys.

Bayer said last year it would lean more strongly on external firms and institutions to jumpstart is development pipeline, which analysts regard as too thin to make up for an expected decline in revenues from its two pharma bestsellers from about 2024.

But iPSC will likely be a crowded field with large companies such as Roche and Fujifilm Holdings - which in 2015 bought Cellular Dynamics International Inc - in the race, as well as biotech firms including Fate Therapeutics and Evotec.

(Addition reporting by Patricia Weiss)

By Ludwig Burger

Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG 2.59% 64.61 Delayed Quote.6.69%
EVOTEC SE -0.55% 18.895 Delayed Quote.8.81%
FATE THERAPEUTICS INC 5.57% 18.57 Delayed Quote.44.74%
ROCHE HOLDING LTD. 1.58% 273.2 Delayed Quote.12.24%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER AG
08/16Materials up Amid Hopes for Stimulus -- Materials Roundup
08/13Bayer and LANXESS to sell their stakes in Currenta to Macquarie Infrastructur..
08/12CORRECTION : Weed Killer-Label story
08/12No-deal Brexit could deepen Europe's shortage of medicines - experts
08/09Materials Down After Trump Comments on Trade Negotiations -- Materials Roundu..
08/09BAYER MEDIATOR : $8 Billion Roundup Settlement Report 'Pure Fiction' -- 4th Upda..
08/09EUROPE : Italy leads European shares lower on political uncertainty
08/09BAYER MEDIATOR : $8 Billion Roundup Settlement Report 'Pure Fiction' -- 3rd Upda..
08/09NEWS HIGHLIGHTS : Top Company News of the Day
08/09NEWS HIGHLIGHTS : Top Company News of the Day
More news
Financials (EUR)
Sales 2019 46 199 M
EBIT 2019 8 364 M
Net income 2019 3 352 M
Debt 2019 37 554 M
Yield 2019 4,42%
P/E ratio 2019 20,2x
P/E ratio 2020 13,7x
EV / Sales2019 2,11x
EV / Sales2020 2,00x
Capitalization 60 140 M
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 77,86  €
Last Close Price 64,49  €
Spread / Highest target 90,7%
Spread / Average Target 20,7%
Spread / Lowest Target -39,9%
EPS Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG6.69%65 567
JOHNSON & JOHNSON1.15%344 517
ROCHE HOLDING LTD.12.24%235 575
ROCHE HOLDING13.20%235 575
MERCK AND COMPANY11.32%213 689
NOVARTIS17.81%202 958